| A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives A Russo, T Franchina, GRR Ricciardi, A Picone, G Ferraro, M Zanghì, ... Oncotarget 6 (29), 26814, 2015 | 181 | 2015 |
| RET fusions in solid tumors AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, ... Cancer treatment reviews 81, 101911, 2019 | 167 | 2019 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 132 | 2020 |
| Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective … A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ... Advances in therapy 37, 1145-1155, 2020 | 110 | 2020 |
| EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ... Nature reviews Clinical oncology 19 (1), 51-69, 2022 | 99 | 2022 |
| Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with … A Russo, T Franchina, GRR Ricciardi, A Battaglia, A Scimone, R Berenato, ... Journal of cellular physiology 233 (10), 6337-6343, 2018 | 98 | 2018 |
| Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going A Russo, T Franchina, GRR Ricciardi, V Smiroldo, M Picciotto, M Zanghi, ... Critical reviews in oncology/hematology 117, 38-47, 2017 | 96 | 2017 |
| Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) C Rolfo, AF Cardona, M Cristofanilli, L Paz-Ares, JJD Mochon, I Duran, ... Critical Reviews in Oncology/Hematology 151, 102978, 2020 | 87 | 2020 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 81 | 2021 |
| Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future … A Russo, T Franchina, G Ricciardi, A Battaglia, M Picciotto, V Adamo International journal of molecular sciences 20 (6), 1431, 2019 | 81 | 2019 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 72 | 2021 |
| NSCLC and HER2: between lights and shadows GRR Ricciardi, A Russo, T Franchina, G Ferraro, M Zanghì, A Picone, ... Journal of Thoracic Oncology 9 (12), 1750-1762, 2014 | 70 | 2014 |
| Liquid biopsy tracking of lung tumor evolutions over time A Russo, D De Miguel Perez, M Gunasekaran, K Scilla, R Lapidus, ... Expert review of molecular diagnostics 19 (12), 1099-1108, 2019 | 59 | 2019 |
| Targeted therapies in early stage NSCLC: hype or hope? A Friedlaender, A Addeo, A Russo, V Gregorc, D Cortinovis, CD Rolfo International journal of molecular sciences 21 (17), 6329, 2020 | 56 | 2020 |
| Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient G Rossi, A Russo, M Tagliamento, A Tuzi, O Nigro, G Vallome, C Sini, ... Cancers 12 (5), 1125, 2020 | 53 | 2020 |
| Precision prevention and cancer interception: the new challenges of liquid biopsy MJ Serrano, MC Garrido-Navas, JJ Diaz Mochon, M Cristofanilli, ... Cancer discovery 10 (11), 1635-1644, 2020 | 50 | 2020 |
| Radiomic detection of EGFR mutations in NSCLC G Rossi, E Barabino, A Fedeli, G Ficarra, S Coco, A Russo, V Adamo, ... Cancer research 81 (3), 724-731, 2021 | 49 | 2021 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 47 | 2020 |
| Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario G Rossi, A Pezzuto, C Sini, A Tuzi, F Citarella, MG McCusker, O Nigro, ... Critical Reviews in Oncology/Hematology 142, 26-34, 2019 | 46 | 2019 |
| New targets in lung cancer (excluding EGFR, ALK, ROS1) A Russo, AR Lopes, MG McCusker, SG Garrigues, GR Ricciardi, ... Current Oncology Reports 22, 1-14, 2020 | 41 | 2020 |
Christian RolfoProfessor in Oncology, Head of Phase I -Early Clinical Trials Unit, Oncology, Antwerp UniversityVerified email at uza.be
